Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, Randomized, Placebo-Controlled Study on the Role of the LC-NA System in Experimental Sleep Fragmentation With Buccal Dexmedetomidine.

NCT07167316 is registered in ClinicalTrials.gov with Hans-Peter Landolt as lead sponsor.

NCT NCT07167316
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07167316 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, Randomized, Placebo-Controlled Study on the Role of the LC-NA System in Experimental Sleep Fragmentation With Buccal Dexmedetomidine.
Lead sponsor
Hans-Peter Landolt
Phase
Phase 1
Overall status
Recruiting
Start date
May 21, 2026
Completion date
October 1, 2027
Enrollment
42 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

the role of the lc-na system in sleep regulation